The Masonic Cancer Center team is saddened by the loss of Judy Erdahl, a longtime friend, and an advocate of the cancer center.
Judy passed away this morning surrounded by loved ones after a lengthy battle with metastatic breast cancer. She is survived by her husband Steve, and their two adult sons, Luke and Ranen.
Emil Lou, MD, PhD, FACP, Assistant Professor of Medicine, Division of Hematology, Oncology, and Transplantation (HOT), has been appointed Medical Director of the Masonic Cancer Center Clinical Trials Office (CTO). This new role will begin on September 1, 2019.
MINNEAPOLIS - A team led by Reuben Harris, PhD, Professor in the Department of Biochemistry, Molecular Biology, and Biophysics (BMBB), and Douglas Yee, MD, Director of the Masonic Cancer Center, and Professor in the Department of Medicine and Pharmacology, were recently awarded a multi-million dollar program project grant P01 from the National Cancer Institute (NCI).
Shernan Holtan, MD, Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation and a Hematologist/Oncologist with University of Minnesota Health, was appointed as the Medical Director of the Masonic Cancer Center Clinical Trials Office-Cellular, Gene and Immunotherapy (CTO-CGI) earlier this year.
MINNEAPOLIS/ST. PAUL (July 23, 2019) – Distinguished surgeon-scientist, Andrew Venteicher, MD, PhD, has joined the University of Minnesota Medical School’s Department of Neurosurgery and the Masonic Cancer Center, where he will be leading key research initiatives in the genomics of brain tumors as the Director of Center for Cranial Base Surgery.
The Pancreatic Cancer Action Network (PanCAN) announced the recipients of its 2019 research grants. Through a highly competitive peer-review process, seven researchers across the U.S. were selected, bringing PanCAN’s total projected research investment to approximately $104 million, including its grants program and clinical and scientific initiatives.
There are more than 15 million cancer survivors in the world today, each living with the systemic impacts of their cancer treatments. Survivorship research focuses on the myriad of issues cancer treatments cause and seeks to maximize patient quality of life after the therapy.